Lifetime perspectives on dementia prevention: The role of ‘preventive’ polypharmacy

      Within the new reality of multimorbidity, co-occurrence of chronic diseases necessitates frequent and simultaneous use of multiple medications. These combinations of medications easily lead to the simultaneous use of 5 or more drugs (‘polypharmacy’). Contrary to widespread belief, it has been shown that preventive cardiovascular medications form the backbone of polypharmacy among adults, present in up to 90 % of all occurrences of polypharmacy on a population-level [
      • Licher S.
      • et al.
      Epidemiology of polypharmacy in the general population: 27-year prospective cohort study.
      ]. Is this a sign of preventive health or are these preventive drugs part of inappropriate polypharmacy that could potentially harm cognitive health?


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Licher S.
        • et al.
        Epidemiology of polypharmacy in the general population: 27-year prospective cohort study.
        J. Am. Med. Dir. Assoc. 2020; 21: 1177-1179
        • Mangin D.
        • et al.
        International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): position statement and 10 recommendations for action.
        Drugs Aging. 2018; 35: 575-587
        • SPRINT MIND Investigators for the SPRINT Research Group
        Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial.
        JAMA. 2019; 321: 553-561
        • Mortensen M.B.
        • Nordestgaard B.G.
        Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort.
        Lancet. 2020; 396: 1644-1652
        • van der Ploeg M.A.
        • et al.
        Recommendations for (discontinuation of) statin treatment in older adults: review of guidelines.
        J. Am. Geriatr. Soc. 2020; 68: 417-425